Please use this identifier to cite or link to this item: https://scidar.kg.ac.rs/handle/123456789/16057
Title: Advancements in neuroactive peptides in seizures
Authors: Jankovic, Slobodan
Đešević M.
Issue Date: 2022
Abstract: Introduction: Neuroactive peptides are peptides produced by neurons and released through controlled mechanisms that bind to specific receptors on nerve, glial, or other cell types, causing biochemical response(s) within these cells. Areas covered: This article summarizes and interprets recent advancements in our knowledge of neuroactive peptides with pro- or anti-convulsant action, and about new drugs that use the molecular machinery of neuroactive peptides to suppress seizures. Expert opinion: According to the results of preclinical and limited clinical investigations to date, the highest potential to become anti-epileptic drugs with marketing authorization belongs to non-peptide agonists of melanocortin receptors, thyrotropin-releasing hormone receptors, ghrelin receptors, galanin receptors, somatostatin and cortistatin receptors, oxytocin receptors, cholecystokinin receptors, and opioid kappa receptors, followed by non-peptide antagonists of the renin-angiotensin system, corticotropin-releasing hormone receptors, NK1 receptors for substance P, arginine-vasopressin receptors, and opioid delta receptors.
URI: https://scidar.kg.ac.rs/handle/123456789/16057
Type: review
DOI: 10.1080/14737175.2022.2031983
ISSN: 1473-7175
SCOPUS: 2-s2.0-85124242711
Appears in Collections:Faculty of Medical Sciences, Kragujevac

Page views(s)

52

Downloads(s)

1

Files in This Item:
File Description SizeFormat 
PaperMissing.pdf
  Restricted Access
29.86 kBAdobe PDFThumbnail
View/Open


Items in SCIDAR are protected by copyright, with all rights reserved, unless otherwise indicated.